Effects of topical dorzolamide on retinal and retrobulbar hemodynamics

Alon Harris, Oliver Arend, Suzanne Arend, Bruce Martin

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: Topical carbonic anhydrase inhibitors such as dorzolamide have been developed as ocular hypotensive agents devoid of the side effects plaguing their systemic predecessors. We evaluated the influence of dorzolamide on retinal and retrobulbar blood how markers to determine if the drug has orbital vascular as well as ocular hypotensive effects. Methods: Eleven persons with healthy eyes received either placebo or two drops 2% dorzolamide, 2 h prior to studies conducted in double-masked, counterbalanced fashion. Four retrobulbar vessels (nasal and temporal posterior ciliary, central retinal, and ophthalmic arteries) were analyzed by color Doppler imaging; scanning laser ophthalmoscopy was used to examine retinal and superficial optic nerve head blood linear velocity. Results: Dorzolamide lowered IOP from 15.7 ± 0.7 to 13.7 ± 0.7 mmHg (p < 0.05). The drug also hastened retinal arteriovenous passage of fluorescein dye, and accelerated capillary dye transit in the macula and optic nerve head. The drug, however, left unaltered blood velocity or resistance index in any retrobulbar vessel. Conclusions: Dorzolamide is an effective ocular hypotensive agent that accelerates blood velocity in the retinal and superficial optic nerve head without an apparent effect upon retrobulbar hemodynamics.

Original languageEnglish (US)
Pages (from-to)569-572
Number of pages4
JournalActa Ophthalmologica Scandinavica
Volume74
Issue number6
StatePublished - Dec 1 1996

Fingerprint

dorzolamide
Hemodynamics
Optic Disk
Coloring Agents
Pharmaceutical Preparations
Ophthalmic Artery
Retinal Artery
Carbonic Anhydrase Inhibitors
Ophthalmoscopy
Fluorescein
Nose
Blood Vessels
Lasers
Color
Placebos

Keywords

  • Carbonic anhydrase
  • Central retinal artery
  • Intraocular pressure
  • Ophthalmic artery

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. / Harris, Alon; Arend, Oliver; Arend, Suzanne; Martin, Bruce.

In: Acta Ophthalmologica Scandinavica, Vol. 74, No. 6, 01.12.1996, p. 569-572.

Research output: Contribution to journalArticle

Harris, Alon ; Arend, Oliver ; Arend, Suzanne ; Martin, Bruce. / Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. In: Acta Ophthalmologica Scandinavica. 1996 ; Vol. 74, No. 6. pp. 569-572.
@article{c75c5fbc96464f14b549417455b294cf,
title = "Effects of topical dorzolamide on retinal and retrobulbar hemodynamics",
abstract = "Purpose: Topical carbonic anhydrase inhibitors such as dorzolamide have been developed as ocular hypotensive agents devoid of the side effects plaguing their systemic predecessors. We evaluated the influence of dorzolamide on retinal and retrobulbar blood how markers to determine if the drug has orbital vascular as well as ocular hypotensive effects. Methods: Eleven persons with healthy eyes received either placebo or two drops 2{\%} dorzolamide, 2 h prior to studies conducted in double-masked, counterbalanced fashion. Four retrobulbar vessels (nasal and temporal posterior ciliary, central retinal, and ophthalmic arteries) were analyzed by color Doppler imaging; scanning laser ophthalmoscopy was used to examine retinal and superficial optic nerve head blood linear velocity. Results: Dorzolamide lowered IOP from 15.7 ± 0.7 to 13.7 ± 0.7 mmHg (p < 0.05). The drug also hastened retinal arteriovenous passage of fluorescein dye, and accelerated capillary dye transit in the macula and optic nerve head. The drug, however, left unaltered blood velocity or resistance index in any retrobulbar vessel. Conclusions: Dorzolamide is an effective ocular hypotensive agent that accelerates blood velocity in the retinal and superficial optic nerve head without an apparent effect upon retrobulbar hemodynamics.",
keywords = "Carbonic anhydrase, Central retinal artery, Intraocular pressure, Ophthalmic artery",
author = "Alon Harris and Oliver Arend and Suzanne Arend and Bruce Martin",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "74",
pages = "569--572",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effects of topical dorzolamide on retinal and retrobulbar hemodynamics

AU - Harris, Alon

AU - Arend, Oliver

AU - Arend, Suzanne

AU - Martin, Bruce

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Purpose: Topical carbonic anhydrase inhibitors such as dorzolamide have been developed as ocular hypotensive agents devoid of the side effects plaguing their systemic predecessors. We evaluated the influence of dorzolamide on retinal and retrobulbar blood how markers to determine if the drug has orbital vascular as well as ocular hypotensive effects. Methods: Eleven persons with healthy eyes received either placebo or two drops 2% dorzolamide, 2 h prior to studies conducted in double-masked, counterbalanced fashion. Four retrobulbar vessels (nasal and temporal posterior ciliary, central retinal, and ophthalmic arteries) were analyzed by color Doppler imaging; scanning laser ophthalmoscopy was used to examine retinal and superficial optic nerve head blood linear velocity. Results: Dorzolamide lowered IOP from 15.7 ± 0.7 to 13.7 ± 0.7 mmHg (p < 0.05). The drug also hastened retinal arteriovenous passage of fluorescein dye, and accelerated capillary dye transit in the macula and optic nerve head. The drug, however, left unaltered blood velocity or resistance index in any retrobulbar vessel. Conclusions: Dorzolamide is an effective ocular hypotensive agent that accelerates blood velocity in the retinal and superficial optic nerve head without an apparent effect upon retrobulbar hemodynamics.

AB - Purpose: Topical carbonic anhydrase inhibitors such as dorzolamide have been developed as ocular hypotensive agents devoid of the side effects plaguing their systemic predecessors. We evaluated the influence of dorzolamide on retinal and retrobulbar blood how markers to determine if the drug has orbital vascular as well as ocular hypotensive effects. Methods: Eleven persons with healthy eyes received either placebo or two drops 2% dorzolamide, 2 h prior to studies conducted in double-masked, counterbalanced fashion. Four retrobulbar vessels (nasal and temporal posterior ciliary, central retinal, and ophthalmic arteries) were analyzed by color Doppler imaging; scanning laser ophthalmoscopy was used to examine retinal and superficial optic nerve head blood linear velocity. Results: Dorzolamide lowered IOP from 15.7 ± 0.7 to 13.7 ± 0.7 mmHg (p < 0.05). The drug also hastened retinal arteriovenous passage of fluorescein dye, and accelerated capillary dye transit in the macula and optic nerve head. The drug, however, left unaltered blood velocity or resistance index in any retrobulbar vessel. Conclusions: Dorzolamide is an effective ocular hypotensive agent that accelerates blood velocity in the retinal and superficial optic nerve head without an apparent effect upon retrobulbar hemodynamics.

KW - Carbonic anhydrase

KW - Central retinal artery

KW - Intraocular pressure

KW - Ophthalmic artery

UR - http://www.scopus.com/inward/record.url?scp=0030454243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030454243&partnerID=8YFLogxK

M3 - Article

C2 - 9017044

AN - SCOPUS:0030454243

VL - 74

SP - 569

EP - 572

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 6

ER -